BTIG Research Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price objective decreased by equities researchers at BTIG Research from $290.00 to $260.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. BTIG Research’s price target points to a potential upside of 24.32% from the stock’s previous close.

IQV has been the topic of several other reports. UBS Group lifted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley upped their price target on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their target price for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $261.24.

IQVIA Price Performance

Shares of IQV stock traded up $3.31 on Friday, hitting $209.13. 893,041 shares of the company’s stock were exchanged, compared to its average volume of 1,083,172. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market cap of $38.12 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.11 and a beta of 1.49. IQVIA has a 12 month low of $181.03 and a 12 month high of $261.73. The company has a 50 day moving average of $235.10 and a 200 day moving average of $229.89.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the business. Capital Performance Advisors LLP bought a new position in IQVIA during the third quarter worth $27,000. Principal Financial Group Inc. raised its holdings in shares of IQVIA by 0.8% during the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock valued at $49,532,000 after purchasing an additional 1,750 shares during the period. Malaga Cove Capital LLC boosted its position in shares of IQVIA by 17.1% during the 3rd quarter. Malaga Cove Capital LLC now owns 1,373 shares of the medical research company’s stock worth $325,000 after purchasing an additional 200 shares in the last quarter. Graypoint LLC grew its stake in shares of IQVIA by 6.3% in the 3rd quarter. Graypoint LLC now owns 1,262 shares of the medical research company’s stock valued at $299,000 after buying an additional 75 shares during the period. Finally, Concurrent Investment Advisors LLC increased its position in IQVIA by 5.6% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 5,679 shares of the medical research company’s stock valued at $1,346,000 after buying an additional 301 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.